

TruSight™ Oncology 500 ctDNA v2

Enabling sensitive, fast CGP
from liquid biopsy samples



Detect biomarkers present as low as 0.2% VAF from 20 ng ctDNA (5–30 ng possible)



Obtain comprehensive results in 2.5–4 days with manual or automated options



Analyze > 500 genes and immuno-oncology (IO) genomic signatures (bMSI, bTMB) in one assay



Leverage transformative economics and small batch sizes with the NextSeq™ 2000 System and the NovaSeq™ X Series

The value ctDNA and liquid biopsy bring to CGP

Understanding the genomic basis of cancer can help pinpoint alterations that fuel the disease, enabling biomarker discovery and advancements in precision medicine. Among the tools used in oncology research is comprehensive genomic profiling (CGP). Next-generation sequencing (NGS) can enhance CGP by facilitating the assessment of a wide range of biomarkers in a single assay, using less sample and returning results faster than multiple, iterative testing strategies.^{1,2} In addition, CGP tests can identify more variants of interest than conventional testing approaches, such as single-gene tests and hotspot NGS panels.³⁻⁶ This ability to detect more variants grows in importance as an increasing number of biomarkers are discovered, including immunology (IO) genomic signatures such as tumor mutational burden (TMB) that require large NGS panels (> 1 Mb) for accurate identification.^{7,8}

The standard approach for CGP relies on solid tumor tissue samples, typically formalin-fixed, paraffin-embedded (FFPE) specimens. However, in up to 25% of cases, tissue is inadequate for testing, the tumor is inaccessible, or the process does not yield results within a useful timeframe. In these cases, performing CGP with circulating tumor DNA (ctDNA) from a blood-based liquid biopsy can provide insights into the genomic landscape

of the tumor. Detection of ctDNA has been reported across all stages of cancer progression and in multiple solid tumor types, including lung, breast, colorectal, and ovarian cancers.¹⁰

Using ctDNA for CGP has several advantages:

- Access sample easily through a minimally invasive blood draw procedure¹¹
- Capture clones from multiple tumors or even the same tumor,¹² overcoming inherent sampling bias present with solid tumor biopsy and expanding the ability to identify more alterations¹²⁻¹⁵
- Obtain temporal and spatial information about intra- and inter-tumor heterogeneity¹¹
- Repeat analysis to assess clonal selection

Liquid biopsy provides a noninvasive approach to obtaining cell-free DNA (cfDNA), which includes ctDNA, from blood plasma for tumor profiling (Figure 1). For certain tumor types, such as non-small cell lung cancer (NSCLC), adding CGP from liquid biopsy to tissue testing can increase the identification of variants by 15–48%.^{13,14,16} In addition, studies of NSCLC show high concordance between cfDNA- and tissue-based analyses.¹⁴ Liquid biopsy is an active area of research, driven by the need for alternatives when tissue samples are limited or unavailable.¹⁷⁻¹⁹




Figure 1: Liquid biopsy enables a noninvasive approach for CGP

A simple blood draw yields ctDNA from cell-free (cfDNA) in plasma, which is then analyzed using TruSight Oncology 500 ctDNA v2 to detect cancer-relevant biomarkers referenced in evidence-based guidelines.

bMSI, blood-based microsatellite instability; bTMB, blood-based tumor mutational burden; CGP, comprehensive genomic profiling; ctDNA, circulating tumor DNA.

TruSight Oncology 500 ctDNA v2

A robust liquid biopsy assay requires a highly sensitive and specific assay capable of detecting low-frequency somatic mutations in ctDNA. The original TruSight Oncology 500 ctDNA assay met this need by leveraging proven Illumina NGS technology to deliver analytical sensitivity.²⁰

TruSight Oncology 500 ctDNA v2 incorporates advances in chemistry and workflow efficiency that improve assay performance and enable faster turnaround times (Table 1 and Table 2). The improved analytical performance supports reliable detection of low-frequency variants (Table 3). In addition, the assay is compatible with Illumina mid-throughput and high-capacity sequencing systems, enabling laboratories to select the configuration that best aligns with their study designs (Table 4).

Table 1: TruSight Oncology 500 ctDNA v2 advances

Benefit	TruSight Oncology 500 ctDNA v2	TruSight Oncology 500 ctDNA
Improved assay sensitivity	Separate end-repair and A-tailing steps provide cleaner, more efficient library preparation	Combined end-repair and A-tailing
More streamlined workflow and improved user experience	Plate-based indexes/UMIs reduce handling steps	Tube-based indexes/UMIs
Faster, single day workflow	Single hybridization-capture step	Two hybridization-capture steps
More scalability	192 indexes	16 indexes
Broader batch sizes	4–64 samples ^a	8–48 samples
Automation enabled	Yes	No
<p>a. Batches of four samples are available on the NextSeq 2000 System, NovaSeq 6000 System, and NovaSeq X Series. UMI, unique molecular identifier.</p>		

Table 2: TruSight Oncology 500 ctDNA v2 specifications

Parameter	TruSight Oncology 500 ctDNA v2
Automation capability	<ul style="list-style-type: none"> Hamilton NGS STAR MOA Beckman Coulter Life Sciences Biomek i7 Hamilton NGS STARlet (coming soon)
Hands-on time	<ul style="list-style-type: none"> 8–24 samples (manual): ~2.5 hr 8–24 samples (automated): ~1.5 hr 48 samples (manual): ~4.5 hr 48 samples (automated): ~1.5 hr
Library preparation time ^a	<ul style="list-style-type: none"> 8–24 samples (manual): ~8.5 hr 8–24 samples (automated): ~9.5 hr 48 samples (manual): ~10 hr 48 samples (automated): ~11 hr
Library preparation	<ul style="list-style-type: none"> 24-sample (manual) 48-sample (automated)
Panel size	1.94 Mb DNA
Panel content	<ul style="list-style-type: none"> 523 genes for small variants 59 genes for CNVs 23 genes for gene rearrangements bMSI (> 2300 loci) bTMB (> 1 Mb)
Sample type	cfDNA derived from blood plasma
DNA input	20 ng cfDNA (5–30 ng possible) ^b
Sequence run read length	2 × 151 bp
Sequence	35,000×
Secondary analysis time ^c	<ul style="list-style-type: none"> 4 samples: 1 hr 45 min 8 samples: 2 hr 15 min 24 samples: 3 hr 64 samples: 4 hr 10 min
Bioinformatics features	<ul style="list-style-type: none"> SNV, MNV, indel, CNV, fusion calling, bMSI, and bTMB Advanced UMI, noise-reduction, and error correction algorithms Fragmentomics-based CHIP variant filtering Germline variant filtering, including database- and proximity-based Max Somatic VAF for tumor fraction estimation Contamination detection optimized for rearranged genomes
<p>a. Includes library preparation, enrichment, and bead-based normalization. b. Recommend quantification with Agilent TapeStation or Fragment Analyzer systems. To learn more about input amounts, read the Using lower input amounts with TruSight Oncology ctDNA v2 technical note. c. Times listed correspond to analysis time in Illumina Connected Analytics (cloud) and include 0.5 hr queuing time; queue times may vary. CNV, copy number variation; bMSI, blood-based microsatellite instability; bTMB, blood-based tumor mutational burden; UMI, unique molecular identifiers; VAF, variant allele frequency.</p>	

Table 3: TruSight Oncology 500 ctDNA v2 assay performance^a

Parameter	Analytical sensitivity ^b	Analytical specificity ^c
Small DNA variants <ul style="list-style-type: none"> • SNV \geq 0.2% VAF (\geq 0.4% VAF) • SNV hotspots \geq 0.2% VAF • MNV \geq 0.5% VAF • Indels \geq 0.5% VAF 	\geq 90% (\geq 95%)	\geq 99.999%
Gene amplifications \geq 1.3-fold change	\geq 95%	\geq 95%
Gene deletions \leq 0.6-fold change	\geq 95%	\geq 95%
MSI-high detection at 0.3% tumor fraction	\geq 95%	\geq 95%
Gene rearrangements \geq 0.5% VAF	\geq 95%	$>$ 95%

a. Performance characteristics were measured on NovaSeq 6000 System using 20 ng of cfDNA and 35,000x coverage, as recommended. Equivalent performance was shown on the NextSeq 2000 System and NovaSeq X Series

b. Analytical sensitivity is defined as percent detection at the stated variant level.

c. Analytical specificity is defined as the ability to detect a known negative.

MNV, multinucleotide variant; SNV, single nucleotide variant; VAF, variant allele frequency.

Table 4: TruSight Oncology 500 ctDNA v2 sequencing system compatibility

Parameter	TruSight Oncology 500 ctDNA v2		
	NextSeq 2000 System	NovaSeq 6000 System or 6000Dx Instrument ^a	NovaSeq X Series
No. samples per flow cell (flow cell)	4 (P4)	4 (S1) 8 (S2)	4 (1.5B) 24 (10B)
Sample throughput (per run)	4	4–48	4–128
Sequence run time	44 hr	25–44 hr	22–48 hr
Total assay time	3 days	2.5–3.5 days	2.5–4 days

a. In RUO mode.

Comprehensive content

The TruSight Oncology 500 ctDNA v2 content was designed with recognized authorities in the oncology community. It includes current and emerging biomarkers with comprehensive coverage of genes referenced in evidence-based guidelines and clinical trials for multiple tumor types. The panel probe design captures both known and novel gene rearrangements and includes 523 genes for detecting variants likely to play a role in tumorigenesis now and in the future ([Appendix](#)). Biomarkers include single nucleotide variants (SNVs), multinucleotide variants (MNVs), insertions/deletions (indels), copy number variants (CNVs), gene rearrangements, and complex IO genomic signatures, such as blood-based microsatellite instability (bMSI) and blood-based TMB (bTMB) ([Table 5](#)).



For a complete list of genes, visit the [TruSight Oncology 500 ctDNA v2 product page](#).

Table 5: Examples of variant types detected by TruSight Oncology 500 ctDNA v2

Variant type	Example
SNVs and indels	<i>EGFR, POLE, TMPRSS2, BRAF</i>
Gene rearrangements	<i>ALK, ROS1, NTRK1, NTRK2, RET</i>
CNVs	<i>HER2</i>
bMSI	bMSI score
bTMB	bTMB score

bMSI, blood-based microsatellite instability; bTMB, blood-based tumor mutational burden; CNV, copy number variant; SNV, single nucleotide variant.

Fast, integrated workflow

TruSight Oncology 500 ctDNA v2 is part of an integrated workflow that spans from sample input to results report (Figure 2). Automated library preparation kits and methods, variant calling tools, and interpretation and reporting software enable a smooth workflow that can be completed in 2.5 days, less than half the time of other liquid biopsy assays (Figure 3).




Figure 2: TruSight Oncology 500 ctDNA v2 workflow

TruSight Oncology 500 ctDNA v2 integrates into current lab workflows, going from cfDNA to a variant report in as little as 2.5 days. DRAGEN TruSight Oncology 500 ctDNA Analysis Software runs locally on a DRAGEN Server or in the cloud via Illumina Connected Analytics.

a. NovaSeq 6000Dx Instrument in RUO mode.

cfDNA, cell-free DNA; CGW, clinical genomics workspace.

TruSight Oncology 500 ctDNA v2

2.5–4 days

Distributed kits 1²² and 2²³

5 days

Distributed kit 3²⁴

8 days

Figure 3: Faster time to results report with TruSight Oncology 500 ctDNA v2

A comparison of the turnaround time from sample to results report for liquid biopsy CGP assays that include the IO biomarkers bMSI and bTMB and other assays. Comparator kits cited are research use only.

bMSI, blood-based microsatellite instability; bTMB, blood-based tumor mutational burden; CGP, comprehensive genomic profiling; IO, immuno-oncology.

Optimized library preparation


Using proven Illumina sequencing by synthesis (SBS) chemistry, TruSight Oncology 500 ctDNA v2 enables CGP from just 20 ng cfDNA, making it an ideal alternative for use when tissue is not readily available or as a complement to tissue studies. Because ctDNA comprises a small fraction of total cfDNA, often less than 5%, powerful methods are required to separate signal from noise. To enable ultra-low frequency variant identification, library preparation uses target enrichment with biotinylated probes and streptavidin-coated magnetic beads to enrich for selected targets from DNA-based libraries (Figure 4). Unique molecular identifiers (UMIs) are also incorporated to reduce errors.²¹ Advances in the product chemistry have decreased the number of hybridizations from two to one, allowing for a one-day turnaround time for library preparation and a shorter time to results. Analytical sensitivity is also improved, down to 0.2% variant allele frequency (VAF) for SNVs. This targeted hybridization–capture approach reduces sample dropouts in the presence of both natural allelic variations and sequence artifacts.

 Learn about [using input amounts as low as 5 ng with TruSight Oncology ctDNA v2](#).

 Learn about [UMIs](#).

Automation-enabled workflow

TruSight Oncology 500 ctDNA v2 supports both manual and automated library preparation to enable scalable workflows. Illumina has partnered with Hamilton and Beckman Coulter Life Sciences, both leaders in liquid handling automation, to develop fully automated workflows for the assay on the Hamilton NGS STAR MOA and the Beckman Coulter Biomek i7 platforms. The automation-compatible library preparation kits include sufficient reagents to prepare 48 libraries while accounting for the dead volume required by automated systems, minimizing reagent waste. These automated workflows deliver the same high-quality results as manual protocols while reducing hands-on time by approximately 40%. In addition, automation helps laboratories lower labor costs and improve operational efficiency.²⁶



Powerful sequencing

TruSight Oncology 500 ctDNA v2 libraries are sequenced on the NextSeq 2000 System, NovaSeq 6000 System, NovaSeq 6000Dx Instrument (RUO mode), or NovaSeq X Series.

The NextSeq 2000 System and the NovaSeq X Series use XLEAP-SBS™ chemistry, which provides higher output, speed, and cost-effectiveness. When running TruSight Oncology 500 ctDNA v2 on the NovaSeq X Series, users benefit from transformative economics by reducing the cost of sequencing per sample.²⁷ In addition, the NovaSeq X Series offers a faster workflow, shortening sequencing time by approximately 40% compared to the NovaSeq 6000 System (Table 6).

Implementation of TruSight Oncology 500 ctDNA v2 on the NextSeq 2000 System makes CGP from liquid biopsy samples accessible to laboratories that prefer a benchtop instrument for low- and mid-throughput sequencing. Even with smaller batches, the NextSeq 2000 System

enables cost-effective sequencing and supports completion of the entire workflow, from extracted nucleic acids to insights, in three days.

Regardless of the platform used, sequencing occurs at high depth (400M reads per sample at ~35,000×) to enhance sensitivity. As a result, variants can be detected at 0.2% VAF for SNVs, with ≥ 90% analytical sensitivity and ≥ 99% analytical specificity (Table 3).

Accurate, accelerated analysis

Comprehensive, efficient variant calling

DRAGEN TruSight Oncology 500 ctDNA Analysis Software uses accelerated, fully integrated algorithms to perform sequence alignment, error correction by collapsing the sequence, then variant calling based on the raw data. Duplicated reads and sequencing errors are removed without losing signal for low-frequency variants while yielding high-sensitivity variant calling results.

Table 6: End-to-end turnaround times

Configuration			Run time				
System	Flow cell	No. of samples	Library prep (manual)	Sequencing	DRAGEN secondary analysis ^a	Connected Insights case reporting	Total
NextSeq 2000	P4	4	8.5 hr	44 hr	1 hr 45 min	20 min	~ 3 days
NovaSeq 6000/ NovaSeq 6000Dx ^b	S1	4	8.5 hr	25 hr	1 hr 45 min	20 min	~ 2.5 days
	S2	8	8.5 hr	36 hr	2 hr 15 min	50 min	~ 3 days
	S4	24	8.5 hr	44 hr	3 hr	2 hr 30 min	~ 3.5 days
NovaSeq X	1.5B	4	8.5 hr	22 hr	1 hr 45 min	20 min	~ 2.5 days
	10B	24	8.5 hr	25 hr	3 hr	2 hr 30 min	~ 3 days
	25B	64	10 hr	48 hr	4 hr 10 min	6 hr 40 min	~ 4 days

a. Times listed correspond to analysis time in Illumina Connected Analytics (cloud) and include 0.5 hr queuing time; queue times may vary.

b. NovaSeq 6000Dx Instrument in RUO mode.

Unlike qualitative results from PCR-based assays, DRAGEN TruSight Oncology 500 ctDNA analysis pipeline provides a quantitative bMSI score derived from > 2300 homopolymer MSI marker sites. For bTMB analysis, the DRAGEN pipeline optimizes sensitivity by measuring both nonsynonymous and synonymous SNVs and indels. After variant calling and error correction, the accuracy of bTMB measurement is further enhanced by filtering germline variants, low-confidence variants, and variants associated with clonal hematopoiesis of indeterminate potential.

DRAGEN TruSight Oncology 500 ctDNA Analysis Software runs locally on an Illumina DRAGEN Server v4 or in the cloud via Illumina Connected Analytics, which offers automated data transfer and analysis launch. This secure, scalable cloud-based solution both speeds up secondary analysis (Table 7) and eliminates the need to acquire and maintain local infrastructure.²⁸

Table 7: Analysis time for DRAGEN TruSight Oncology 500 ctDNA software^a

No. of samples	Illumina Connected Analytics (cloud) ^b	DRAGEN server (local)
4	1 hr 45 min	3 hr
8	2 hr 15 min	7 hr
24	3 hr	19 hr
64	4 hr 10 min	43 hr

a. Times were generated using v2.6.3

b. Times listed include 0.5 hr queuing time; queue times may vary.

Streamlined data interpretation

After variants are identified through secondary analysis, the next step is to derive biologically meaningful insights. TruSight Oncology 500 ctDNA v2 can be used with multiple commercial variant interpretation solutions. Illumina Connected Insights offers the most integrated experience for DRAGEN TruSight Oncology 500 ctDNA data and enables a fully automated analysis workflow that eliminates the need for manual data transfers.

The Connected Insights software incorporates more than 55 knowledge sources, including the Cancer Knowledgebase (CKB) by Genomenon and OncoKB by the Memorial Sloan Kettering Cancer Center, to support variant interpretation. It also allows laboratories to curate and reuse their own variant classifications. Illumina Connected Insights is optimized to work with TruSight Oncology 500 ctDNA v2 data. For example, since bMSI status is determined using the Jensen-Shannon distance (JDS) sum score, Illumina Connected Insights allows users to set bMSI thresholds for TruSight Oncology 500 ctDNA v2 independently from those used for tissue biopsy assays, which often rely on the percentage of unstable sites to determine bMSI status.

Visualization tools are also optimized for TruSight Oncology 500 ctDNA v2 data. In addition to coverage graphs (Figure 5) and a genome view, Illumina Connected Insights includes fusion plots to help users with quality control and interpretation of gene rearrangements. The plots display breakpoints, reading frames, protein domains, supporting reads, and other key metrics (Figure 6).

Variant calling files generated locally or in the cloud with Illumina Connected Analytics can be automatically imported into Illumina Connected Insights. Sequencing system integration and autolaunch features automate the entire analysis workflow, eliminating manual data transfers and generating a final, customizable results report.




Figure 5: Assessing gene and exon coverage with Illumina Connected Insights
Coverage across targeted genes and exons is displayed to reveal gaps that may impact variant detection and interpretation.




Figure 6: Gene fusion visualization generated by Illumina Connected Insights
Fusion partners, breakpoints, and supporting read evidence are displayed to assist with quality control and interpretation.

Reliable, reproducible results

TruSight Oncology 500 ctDNA v2 provides sensitive detection of genomic variants and biomarkers in a cfDNA sample, even when present at low levels. To demonstrate the high-quality results achieved with TruSight Oncology 500 ctDNA v2, Illumina performed various studies evaluating the ability to call small DNA variants, CNVs, gene rearrangements, bTMB, and bMSI. Performance results were verified on the NextSeq 2000 System, NovaSeq 6000 System, and NovaSeq X Series.

SNVs and indels

One advantage of target enrichment chemistry is the use of probes designed to be large enough to ensure high binding specificity, while still allowing hybridization to targets containing small mutations. Because SNVs are associated with cancer susceptibility across multiple tumor types, CGP methods must reliably detect these variants at low levels. TruSight Oncology 500 ctDNA v2 detects SNVs and indels present at levels as low as 0.2% or 0.5% VAF, respectively, with high reproducibility (see [Figure 7](#) and [Figure 8](#) for near LOD performance).




Figure 7: High analytical performance for key SNVs near LOD (0.2% VAF)

Synthetic control samples containing known SNVs were diluted to VAF levels ranging from 0.20% to 0.50% and analyzed with TruSight Oncology 500 ctDNA v2. Dilution 1 had a mean VAF of 0.24% (95% C.I. 0.23–0.25) and Dilution 2 had a mean VAF of 0.49% (95% C.I. 0.48–0.52). SNVs were reliably detected at low VAF levels. Results shown were generated on the NovaSeq 6000 System, with equivalent performance observed on the NextSeq 2000 System and NovaSeq X Series.

LOD, limit of detection; SNV, single nucleotide variant; VAF, variant allele frequency.




Figure 8: High analytical performance for indels near LOD (0.5% VAF)

Synthetic control samples containing known insertions and deletions (indels) were diluted targeting VAF levels ranging from 0.20% to 0.50% and analyzed with TruSight Oncology 500 ctDNA v2. Dilution 1 had a mean VAF of 0.29% (95% C.I. 0.26–0.32) and Dilution 2 had a mean VAF of 0.58% (95% C.I. 0.54–0.63). Indels were reliably detected at low VAF levels. Detection of the *BRCA1* variant was lower due to the location of the variant within a highly homopolymeric region, which contributes to elevated background noise. Results shown were generated on the NovaSeq 6000 System, with equivalent performance observed on the NextSeq 2000 System and NovaSeq X Series.

LOD, limit of detection; VAF, variant allele frequency.

CNVs

Copy number changes in genes and tumor types have been linked to tumorigenesis.²⁷ TruSight Oncology 500 ctDNA v2 includes analysis of 59 CNV-associated genes and can call CNVs with a limit of detection at ≥ 1.3 fold for amplifications and ≤ 0.6 for deletions (Table 8).

Table 8: TruSight Oncology 500 ctDNA v2 analytical performance for CNVs

Gene	Expected fold-change	Observed fold-change	Detection rate
Amplifications			
<i>ERBB2</i>	1.5	1.50	100%
<i>MET</i>	1.5	1.55	100%
<i>MYC</i>	1.5	1.27	100%
<i>ERBB2</i>	1.4	1.73	100%
<i>MET</i>	1.4	1.46	100%
<i>MYC</i>	1.4	1.22	100%
<i>ERBB2</i>	1.3	1.35	100%
<i>MET</i>	1.3	1.38	100%
<i>MYC</i>	1.3	1.19	8%
<i>ERBB2</i>	1.2	1.19	100%
<i>MET</i>	1.2	1.22	100%
<i>MYC</i>	1.2	N/A	0
Deletions			
<i>BRCA1</i>	0.85	0.86	16%
<i>BRCA2</i>	0.85	N/A	0
<i>BRCA1</i>	0.80	0.79	100%
<i>BRCA2</i>	0.80	0.80	100%
<i>BRCA1</i>	0.70	0.69	100%
<i>BRCA2</i>	0.70	0.69	100%

Samples containing known gene amplifications, generated from synthetic controls, and known deletions, derived from well-characterized cell lines, were evaluated using TruSight Oncology 500 ctDNA v2 across three VAF levels. The assay demonstrated a LOD of ≥ 1.3 -fold change for amplifications and ≤ 0.6 -fold change for deletions, with strong concordance between expected and observed results. Sequencing data were obtained on the NovaSeq 6000 System; similar performance was observed on the NextSeq 2000 System and the NovaSeq X Series. CNV, copy number variant; LOD, limit of detection; N/A, not applicable.

Gene rearrangements

Gene rearrangements are key genomic drivers of cancer, making sensitive detection critical for studies investigating disease mechanisms. TruSight Oncology 500 ctDNA v2 enables detection and characterization of gene rearrangements independent of the fusion partner, even at low concentrations (Table 9).

Table 9: TruSight Oncology 500 ctDNA v2 analytical performance for gene rearrangements

Fusion	Expected VAF	Observed VAF	Detection rate
<i>ALK:EML4</i>	0.60%	0.48%	100%
<i>GOPC;ROS1:CD74</i>	0.60%	0.39%	100%
<i>RET:NCOA4</i>	0.60%	0.31%	100%
<i>ALK:EML4</i>	0.50%	0.43%	100%
<i>GOPC;ROS1:CD74</i>	0.50%	0.33%	100%
<i>RET:NCOA4</i>	0.50%	0.27%	100%
<i>ALK:EML4</i>	0.40%	0.36%	100%
<i>GOPC;ROS1:CD74</i>	0.40%	0.24%	100%
<i>RET:NCOA4</i>	0.40%	0.19%	100%
<i>ALK:EML4</i>	0.20%	0.18%	88%
<i>GOPC;ROS1:CD74</i>	0.20%	0.11%	100%
<i>RET:NCOA4</i>	0.20%	0.12%	83%

TruSight Oncology 500 ctDNA v2 reliably detected three known DNA fusions diluted to VAF levels as low as 0.2%, with a demonstrated LOD of 0.5% for gene rearrangements. Sequencing data were obtained on the NovaSeq 6000 System; similar performance was observed on the NextSeq 2000 System and the NovaSeq X Series. LOD, limit of detection; VAF, variant allele frequency.

IO gene signatures: bMSI and bTMB

bMSI and bTMB detection requires analysis across numerous genomic loci. TruSight Oncology 500 ctDNA v2 enables NGS-based assessment of more than 2300 homopolymer sites (6–7 bp in length), reducing error rates and minimizing false positives commonly associated with homopolymer sequencing.²⁷ Featuring sensitive library preparation chemistry and advanced bioinformatics, TruSight Oncology 500 ctDNA v2 achieves bMSI detection down to 0.3% tumor fraction (Figure 9).

Accurately and reproducibly determining bTMB at low mutation levels can be challenging with smaller panels.⁷ TruSight Oncology 500 ctDNA v2 overcomes this by combining broad genomic coverage through a 1.94 Mb panel combined with advanced bioinformatics. The proprietary DRAGEN TruSight Oncology 500 ctDNA pipeline applies optimized filtering to exclude germline and clonal hematopoiesis-associated variants, delivering highly concordant tumor-only and tumor-normal workflows ($R^2 = 0.992$) (Figure 10).²⁹




Figure 9: High bMSI analytical sensitivity achieved with TruSight Oncology 500 ctDNA v2

Tumor fractions were generated by titrating nucleosomal-prepared cell lines with known MSI-H status into a wild type cell background. High bMSI analytical sensitivity was achieved using the proprietary DRAGEN TruSight Oncology 500 ctDNA Analysis Software. More than 2300 homopolymer sites were assessed. Sequencing data were obtained on the NovaSeq 6000 System; similar performance was observed on the NextSeq 2000 System and NovaSeq X Series.

CGP, comprehensive genomic profiling; bMSI, blood-based microsatellite instability, MSI-H, microsatellite instability-high.




Figure 10: High bTMB data correlation between tumor-only and tumor-normal analysis workflows

Tumor-only bTMB scores generated with TruSight Oncology 500 ctDNA v2 show high concordance to bTMB scores produced from a paired tumor-normal workflow using plasma and buffy coat cfDNA. Sequencing data were obtained on the NovaSeq 6000 System. bTMB scores were highly concordant with those obtained using the NextSeq 2000 System and NovaSeq X Series.

bTMB, blood-based tumor mutational burden.

Enhanced product attributes

Illumina offers high levels of service and support to ensure operational success for laboratories. To enable greater efficiency, TruSight Oncology 500 ctDNA v2 features:

- Advanced change notification—Illumina notifies laboratories six months in advance of any significant changes to TruSight Oncology 500 ctDNA v2
- Certificate of Analysis—TruSight Oncology 500 ctDNA v2 includes a certificate of analysis (CoA) that confirms the product meets predefined release specifications and quality standards
- Extended shelf life—TruSight Oncology 500 ctDNA v2 reagents have a minimum guaranteed shelf life of six months, reducing the risk of expiration and supporting flexible testing schedules
- Single-lot shipments— TruSight Oncology 500 ctDNA v2 manual kits are available as single-lot shipments to reduce lot qualification and incoming QC burden; automation kit requests may be accommodated on a case-by-case basis via customer care

Integrated solution enabling CGP from liquid biopsy

TruSight Oncology 500 ctDNA v2 is an NGS-based, multiplex research assay that enables simultaneous analysis of hundreds of cancer-related biomarkers from plasma samples, in alignment with current guidelines and evidence from clinical trials. The comprehensive assay detects multiple variant types in blood across 523 genes implicated in diverse tumor types. It also assesses IO and emerging biomarkers, including bTMB, bMSI, *NTRK*, and *ROS1*, all from a single sample, eliminating the need for iterative testing.

The updated assay chemistry and expanded sequencing system compatibility have decreased overall turnaround time to 2.5–4 days, reduced the input requirement to 20 ng cfDNA, and lowered the limit of detection to 0.2% VAF (for SNVs). The automation-enabled workflow further reduces hands-on time and minimizes the burden on laboratory personnel, improving overall efficiency. By combining broad genomic content, proven sequencing technology, and improved software, TruSight Oncology 500 ctDNA v2 simplifies CGP-based research while delivering superior performance for liquid biopsy studies.

Learn more →

[TruSight Oncology 500 ctDNA v2](#)

[NovaSeq 6000 System](#)

[NovaSeq 6000Dx Instrument](#)

[NextSeq 2000 System](#)

[NovaSeq X Series](#)

[DRAGEN secondary analysis](#)

[Illumina Connected Analytics](#)

[Illumina Connected Insights](#)

[Illumina Automated Solutions](#)

Appendix - TruSight Oncology 500 ctDNA v2 gene list^a

ABL1	BCR	CHEK1	EPHA7	FGF8	GSK3B	IDH2	MAP3K1	NF2	PIK3CA	RAD51D	SMAD4	TGFBR2
ABL2	BIRC3	CHEK2	EPHB1	FGF9	H3F3A	IFNGR1	MAP3K13	NFE2L2	PIK3CB	RAD52	SMARCA4	TMEM127
ACVR1	BLM	CIC	ERBB2	FGF10	H3F3B	INHBA	MAP3K14	NFKBIA	PIK3CD	RAD54L	SMARCB1	TMPRSS2
ACVR1B	BMPR1A	CREBBP	ERBB3	FGF14	H3F3C	INPP4A	MAP3K4	NKX2-1	PIK3CG	RAF1	SMARCD1	TNFAIP3
AKT1	BRAF	CRKL	ERBB4	FGF19	HGF	INPP4B	MAPK1	NKX3-1	PIK3R1	RANBP2	SMC1A	TNFRSF14
AKT2	BRCA1	CRLF2	ERCC1	FGF23	HIST1H1C	INSR	MAPK3	NOTCH1	PIK3R2	RARA	SMC3	TOP1
AKT3	BRCA2	CSF1R	ERCC2	FGFR1	HIST1H2BD	IRF2	MAX	NOTCH2	PIK3R3	RASA1	SMO	TOP2A
ALK	BRD4	CSF3R	ERCC3	FGFR2	HIST1H3A	IRF4	MCL1	NOTCH3	PIM1	RB1	SNCAIP	TP53
ALOX12B	BRIP1	CSNK1A1	ERCC4	FGFR3	HIST1H3B	IRS1	MDC1	NOTCH4	PLCG2	RBM10	SOCS1	TP63
ANKRD11	BTG1	CTCF	ERCC5	FGFR4	HIST1H3C	IRS2	MDM2	NPM1	PLK2	RECQL4	SOX10	TRAF2
ANKRD26	BTK	CTLA4	ERG	FH	HIST1H3D	JAK1	MDM4	NRAS	PMAIP1	REL	SOX17	TRAF7
APC	C11orf30	CTNNA1	ERRF1	FLCN	HIST1H3E	JAK2	MED12	NRG1	PMS1	RET	SOX2	TSC1
AR	CALR	CTNNB1	ESR1	FLI1	HIST1H3F	JAK3	MEF2B	NSD1	PMS2	RFWD2	SOX9	TSC2
ARAF	CARD11	CUL3	ETS1	FLT1	HIST1H3G	JUN	MEN1	NTRK1	PNRC1	RHEB	SPEN	TSHR
ARFRP1	CASP8	CUX1	ETV1	FLT3	HIST1H3H	KAT6A	MET	NTRK2	POLD1	RHOA	SPOP	U2AF1
ARID1A	CBFB	CXCR4	ETV4	FLT4	HIST1H3I	KDM5A	MGA	NTRK3	POLE	RICTOR	SPTA1	VEGFA
ARID1B	CBL	CYLD	ETV5	FOXA1	HIST1H3J	KDM5C	MITF	NUP93	PPARG	RIT1	SRC	VHL
ARID2	CCND1	DAXX	ETV6	FOXL2	HIST2H3A	KDM6A	MLH1	NUTM1	PPM1D	RNF43	SRSF2	VTCN1
ARID5B	CCND2	DCUN1D1	EWSR1	FOXO1	HIST2H3C	KDR	MLL	PAK1	PPP2R1A	ROS1	STAG1	WISP3
ASXL1	CCND3	DDR2	EZH2	FOXP1	HIST2H3D	KEAP1	MLL2	PAK3	PPP2R2A	RPS6KA4	STAG2	WT1
ASXL2	CCNE1	DDX41	FAM123B	FRS2	HIST3H3	KEL	MPL	PAK7	PPP6C	RPS6KB1	STAT3	XIAP
ATM	CD274	DHX15	FAM175A	FUBP1	HLA-A	KIF5B	MRE11A	PALB2	PRDM1	RPS6KB2	STAT4	XPO1
ATR	CD276	DICER1	FAM46C	FYN	HLA-B	KIT	MSH2	PARK2	PREX2	RPTOR	STAT5A	XRCC2
ATRX	CD74	DIS3	FANCA	GABRA6	HLA-C	KLF4	MSH3	PARP1	PRKAR1A	RUNX1	STAT5B	YAP1
AURKA	CD79A	DNAJB1	FANCC	GATA1	HNF1A	KLHL6	MSH6	PAX3	PRKCI	RUNX1T1	STK11	YES1
AURKB	CD79B	DNMT1	FANCD2	GATA2	HNRNPK	KMT2B	MST1	PAX5	PRKDC	RYBP	STK40	ZBTB2
AXIN1	CDC73	DNMT3A	FANCE	GATA3	HOXB13	KMT2C	MST1R	PAX7	PRSS8	SDHA	SUFU	ZBTB7A
AXIN2	CDH1	DNMT3B	FANCF	GATA4	IGF1	KMT2D	MTOR	PAX8	PTCH1	SDHAF2	SUZ12	ZFH3
AXL	CDK12	DOT1L	FANCG	GATA6	IGF1R	KRAS	MUTYH	PBRM1	PTEN	SDHB	SYK	ZNF217
B2M	CDK4	E2F3	FANCI	GEN1	IGF2	LAMP1	MYB	PDCD1	PTPN11	SDHC	TAF1	ZNF703
BAP1	CDK6	EED	FANCL	GID4	IKBKE	LATS1	MYC	PDCD1LG2	PTPRD	SDHD	TBX3	ZRSR2
BARD1	CDK8	EGFL7	FAS	GLI1	IKZF1	LATS2	MYCL1	PDGFRA	PTPRS	SETBP1	TCEB1	
BBC3	CDKN1A	EGFR	FAT1	GNA11	IL10	LMO1	MYCN	PDGFRB	PTPRT	SETD2	TCF3	
BCL10	CDKN1B	EIF1AX	FBXW7	GNA13	IL7R	LRP1B	MYD88	PDK1	QKI	SF3B1	TCF7L2	
BCL2	CDKN2A	EIF4A2	FGF1	GNAQ	INHA	LYN	MYOD1	PDPK1	RAB35	SH2B3	TERC	
BCL2L1	CDKN2B	EIF4E	FGF2	GNAS	HRAS	LZTR1	NAB2	PGR	RAC1	SH2D1A	TERT^b	
BCL2L11	CDKN2C	EML4	FGF3	GPR124	HSD3B1	MAGI2	NBN	PHF6	RAD21	SHQ1	TET1	
BCL2L2	CEBPA	EP300	FGF4	GPS2	HSP90AA1	MALT1	NCOA3	PHOX2B	RAD50	SLIT2	TET2	
BCL6	CENPA	EPCAM	FGF5	GREM1	ICOSLG	MAP2K1	NCOR1	PIK3C2B	RAD51	SLX4	TFE3	
BCOR	CHD2	EPHA3	FGF6	GRIN2A	ID3	MAP2K2	NEGR1	PIK3C2G	RAD51B	SMAD2	TFRC	
BCORL1	CHD4	EPHA5	FGF7	GRM3	IDH1	MAP2K4	NF1	PIK3C3	RAD51C	SMAD3	TGFBR1	

a. TruSight Oncology 500 ctDNA v2 detects small variants for all genes listed.

b. Only the *TERT* promoter region is covered for variant calling.

Light orange boxes indicate genes that include copy number variants.

Yellow boxes indicate genes that include DNA fusions.

Dark orange boxes indicate genes that include both copy number variants and DNA fusions.

Probes target at least 97% of the coding sequence for all genes in bold.

Ordering information—Library preparation kits (manual)

Product	Catalog no.
TruSight Oncology 500 ctDNA v2 (24 samples)	20105899
TruSight Oncology 500 ctDNA v2 (24 samples) plus Illumina Connected Insights Software	20105911
TruSight Oncology 500 ctDNA v2 (24 samples) plus Velsera Interpretation Report	20105905
TruSight Oncology 500 ctDNA v2 for use with NextSeq 2000 P4 (24 samples)	20151788
TruSight Oncology 500 ctDNA v2 plus Illumina Connected Insights Software, for use with NextSeq 2000 P4 (24 samples)	20151792
TruSight Oncology 500 ctDNA v2 (24 samples) plus Velsera Interpretation Report, for use with for use with NextSeq 2000 P4 (24 samples)	20151790
TruSight Oncology 500 ctDNA v2 for use with NovaSeq 6000 S2 (24 samples)	20105901
TruSight Oncology 500 ctDNA v2 plus Connected Insights Interpretation Report, for use with NovaSeq 6000 S2 (24 samples)	20105913
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for use with NovaSeq 6000 S2 (24 samples)	20105907
TruSight Oncology 500 ctDNA v2 for use with NovaSeq 6000 S4 (24 samples)	20105902
TruSight Oncology 500 ctDNA v2 plus Connected Insights Interpretation Report, for use with NovaSeq 6000 S2 (24 samples)	20105913
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for use with NovaSeq 6000 S4 (24 samples)	20105908
TruSight Oncology 500 ctDNA v2 plus Connected Insights Interpretation Report, for use with NovaSeq 6000 S4 (24 samples)	20105914

Ordering information—Library preparation kits (automated)

Product	Catalog no.
TruSight Oncology 500 ctDNA v2 for Automation (48 samples)	20105900
TruSight Oncology 500 ctDNA v2 for Automation (48 samples) plus Illumina Connected Insights Software	20105912
TruSight Oncology 500 ctDNA v2 for Automation (48 samples) plus Velsera Interpretation Report	20105906
TruSight Oncology 500 ctDNA v2 Automation Kit, for use with NovaSeq 6000 S2 (48 samples)	20105903
TruSight Oncology 500 ctDNA v2 Automation Kit plus Connected Insights Software, for use with NovaSeq 6000 S2 (48 samples)	20105915
TruSight Oncology 500 ctDNA v2 Automation Kit plus Velsera Interpretation Report, for use with NovaSeq 6000 S2 (48 samples)	20105909
TruSight Oncology 500 ctDNA v2 Automation Kit, for use with NovaSeq 6000 S4 (48 samples)	20105904
TruSight Oncology 500 ctDNA v2 Automation Kit plus Illumina Connected Insights Software, for use with NovaSeq 6000 S4 (48 samples)	20105916
TruSight Oncology 500 ctDNA v2 Automation Kit plus Velsera Interpretation Report, for use with NovaSeq 6000 S4 (48 samples)	20105910

Ordering information—Index adapters

Product	Catalog no.
IDT for Illumina UMI DNA/RNA UD Indexes Set A, Ligation (96 Indexes, 96 Samples)	20034701
IDT for Illumina UMI DNA/RNA UD Indexes Set B, Ligation (96 Indexes, 96 Samples)	20034702
IDT for Illumina UMI DNA/DNA Index Anchors Set A for Automation	20066404
IDT for Illumina UMI DNA/DNA Index Anchors Set B for Automation	20063213
Illumina UMI DNA/RNA UD v3 indexes Set A, Ligation (96 indexes, 96 Samples)	20126235
Illumina UMI DNA/RNA UD v3 indexes Set B, Ligation (96 indexes, 96 Samples)	20126237
Illumina UMI DNA/RNA UD indexes v3, Set A, Auto (96 indexes, 96 Samples)	20141200
Illumina UMI DNA/RNA UD indexes v3, Set B, Auto (96 indexes, 96 Samples)	20141201

Ordering information—Sequencing reagents

Product	Catalog no.
NextSeq 2000 P4 XLEAP-SBS Reagent Kit (300 Cycles)	20100992
NovaSeq 6000 S1 Reagent Kit v1.5 (300 cycles)	20028317
NovaSeq 6000 S2 Reagent Kit v1.5 (300 cycles)	20028314
NovaSeq 6000 S4 Reagent Kit v1.5 (300 cycles)	20028312
NovaSeq X Series 1.5B Reagent Kit (300 cycles)	20104705
NovaSeq X Series 10B Reagent Kit (300 cycles)	20085594
NovaSeq X Series 25B Reagent Kit (300 cycles)	20104706

Ordering information—Analysis

Product	Catalog no.
Local secondary analysis	
Illumina DRAGEN Server v4	20051343
Illumina DRAGEN Server Installation	20031995
Illumina DRAGEN Server v4 Support Plan	20085832
Field Delivered Applications Training	15032919
Cloud-based secondary analysis	
ICA Basic Annual Subscription	20044874
ICA Professional Annual Subscription	20044876
ICA Enterprise Annual Subscription	20038994
ICA Enterprise Compliance Add-on	20066830
Subscription ICA Training and Onboarding	20049422
Variant interpretation	
Illumina Connected Insights – Annual Subscription	20112516
Illumina Connected Insights – Oncology Genome Equivalent Samples (VCF)	20090138
Illumina Connected Insights Training – Remote	20092376
Informatics Professional Services	20071787
Cloud storage	
Illumina Analytics – 1 iCredit	20042038
Illumina Analytics Starter Package – 1000 iCredits	20042039
Illumina Analytics – 5000 iCredits	20042040
Illumina Analytics – 50,000 iCredits	20042041
Illumina Analytics – 100,000 iCredits	20042042

References

- Lim C, Tsao MS, Le LW, et al. **Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.** *Ann Oncol.* 2015;26(7):1415-1421. doi:10.1093/annonc/mdv208
- Yu TM, Morrison C, Gold EJ, Tradonsky A, Layton AJ. **Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of OncoPrint Dx Target Test for advanced non-small-cell lung cancer: a single-center analysis.** *Clin Lung Cancer.* 2019;20(1):20-29.e8. doi:10.1016/j.clcc.2018.08.010
- Reitsma M, Fox J, Borre PV, et al. **Effect of a collaboration between a health plan, oncology practice, and comprehensive genomic profiling company from the payer perspective.** *J Manag Care Spec Pharm.* 2019;25(5):601-611. doi:10.18553/jmcp.2019.18309
- Zehir A, Benayed R, Shah RH, et al. **Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients** [published correction appears in *Nat Med.* 2017 Aug 4;23 (8):1004]. *Nat Med.* 2017;23(6):703-713. doi:10.1038/nm.4333
- Kopetz S, Mills Shaw KR, Lee JJ, et al. **Use of a targeted exome next-generation sequencing panel offers therapeutic opportunity and clinical benefit in a subset of patients with advanced cancers.** *JCO Precis Oncol.* 2019;3:PO.18.00213. doi:10.1200/PO.18.00213
- Drilon A, Wang L, Arcila ME, et al. **Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches.** *Clin Cancer Res.* 2015;21(16):3631-3639. doi:10.1158/1078-0432.CCR-14-2683
- Buchhalter I, Rempel E, Endris V, et al. **Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.** *Int J Cancer.* 2019;144(4):848-858. doi:10.1002/ijc.31878
- Chalmers ZR, Connelly CF, Fabrizio D, et al. **Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.** *Genome Med.* 2017;9(1):34. doi:10.1186/s13073-017-0424-2
- Hagemann IS, Devarakonda S, Lockwood CM, et al. **Clinical next-generation sequencing in patients with non-small cell lung cancer.** *Cancer.* 2015;121(4):631-639. doi:10.1002/cncr.29089
- Bettegowda C, Sausen M, Leary RJ, et al. **Detection of circulating tumor DNA in early- and late-stage human malignancies.** *Sci Transl Med.* 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094
- Saarenheimo J, Eigeliene N, Andersen H, Tirola M, Jekunen A. **The value of liquid biopsies for guiding therapy decisions in non-small cell lung cancer.** *Front Oncol.* 2019;9:129. doi:10.3389/fonc.2019.00129
- Rapisuwon S, Vietsch EE, Wellstein A. **Circulating biomarkers to monitor cancer progression and treatment.** *Comput Struct Biotechnol J.* 2016;14:211-222. doi:10.1016/j.csbj.2016.05.004
- Aggarwal C, Thompson JC, Black TA, et al. **Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer.** *JAMA Oncol.* 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305
- Leighl NB, Page RD, Raymond VM, et al. **Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer.** *Clin Cancer Res.* 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624
- Palmero R, Taus A, Viteri S, et al. **Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small cell lung cancer.** *JCO Precision Oncology.* 2021;5:93-102. doi:10.1200/PO.20.00241
- Mack PC, Banks KC, Espenschied CR, et al. **Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.** *Cancer.* 2020;126(14):3219-3228. doi:10.1002/cncr.32876
- Rolfo C, Mack P, Scagliotti GV, et al. **Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer.** *J Thorac Oncol.* 2021;16(10):1647-1662. doi:10.1016/j.jtho.2021.06.017
- Mosele F, Remon J, Mateo J, et al. **Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.** *Ann Oncol.* 2020;31(11):1491-1505. doi:10.1016/j.annonc.2020.07.014
- Pascual J, Attard G, Bidard FC, et al. **ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.** *Ann Oncol.* 2022;33(8):750-768. doi:10.1016/j.annonc.2022.05.520
- Illumina. TruSight Oncology 500 ctDNA data sheet. illumina.com/content/dam/illumina/gcs/assembled-assets/marketing-literature/trusight-oncology-500-ctdna-data-sheet-m-gl-00843/trusight-oncology-500-ctdna-data-sheet-m-gl-00843.pdf. Accessed September 20, 2023.
- Illumina. TruSight Oncology UMI Reagents data sheet. illumina.com/content/dam/illumina-marketing/documents/products/datasheets/trusight-oncology-umi-reagents-datasheet-1000000050425.pdf. Published 2018. Accessed September 20, 2023.

22. Roche. AVENIO ctDNA Analysis Kits. [Sequencing. sequencing. roche.com/us/en/products/product-category/avenio-ctdna-analysis-kits.html](https://www.roche.com/us/en/products/product-category/avenio-ctdna-analysis-kits.html). Accessed September 20, 2023.
23. Sophia Genetics. [MSK-ACCESS powered with SOPHIA DDM. sophiagenetics.com/sophia-ddm-for-genomics/liquid-biopsy/msk-access/](https://www.sophiagenetics.com/sophia-ddm-for-genomics/liquid-biopsy/msk-access/). Accessed September 26, 2025.
24. Personal Genome Diagnostics. PGDx elio plasma complete. [personalgenome.com/products/elio-plasma-complete](https://www.personalgenome.com/products/elio-plasma-complete). Accessed September 20, 2023.
25. Illumina. Sequencing accuracy with Unique Molecular Identifiers. [illumina.com/techniques/sequencing/ngs-library-prep/multiplexing/unique-molecular-identifiers.html](https://www.illumina.com/techniques/sequencing/ngs-library-prep/multiplexing/unique-molecular-identifiers.html). Accessed September 20, 2023.
26. Socea JN, Stone VN, Qian X, Gibbs PL, Levinson KJ. [Implementing laboratory automation for next-generation sequencing: benefits and challenges for library preparation. Front Public Health. 2023;11:1195581. doi:10.3389/fpubh.2023.1195581](https://doi.org/10.3389/fpubh.2023.1195581)
27. Data on file. Illumina, Inc. 2024.
28. Beroukhim R, Mermel CH, Porter D, et al. [The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463\(7283\):899-905. doi:10.1038/nature08822](https://doi.org/10.1038/nature08822)
29. Illumina. Analysis of TMB and MSI status with TruSight Oncology 500 application note. [illumina.com/content/dam/illumina-marketing/documents/products/appnotes/trusight-oncology-500-tmb-analysis-1170-2018-009.pdf](https://www.illumina.com/content/dam/illumina-marketing/documents/products/appnotes/trusight-oncology-500-tmb-analysis-1170-2018-009.pdf). Published 2018. Accessed September 20, 2023.



1.800.809.4566 toll-free (US) | +1.858.202.4566 tel
techsupport@illumina.com | www.illumina.com

© 2025 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.
M-GL-02196 v6.0